MA38397A1 - Agglomérats inhalables de particules de support poreuses et médicament micronisé - Google Patents

Agglomérats inhalables de particules de support poreuses et médicament micronisé

Info

Publication number
MA38397A1
MA38397A1 MA38397A MA38397A MA38397A1 MA 38397 A1 MA38397 A1 MA 38397A1 MA 38397 A MA38397 A MA 38397A MA 38397 A MA38397 A MA 38397A MA 38397 A1 MA38397 A1 MA 38397A1
Authority
MA
Morocco
Prior art keywords
inhalable
agglomerates
porous carrier
carrier particles
particles
Prior art date
Application number
MA38397A
Other languages
English (en)
French (fr)
Inventor
Michael Hartman
Thomas Tarara
Patrick Teung
Jeffry Weers
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38397A1 publication Critical patent/MA38397A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA38397A 2013-03-14 2014-03-13 Agglomérats inhalables de particules de support poreuses et médicament micronisé MA38397A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784842P 2013-03-14 2013-03-14
PCT/IB2014/059739 WO2014141135A1 (en) 2013-03-14 2014-03-13 Respirable agglomerates of porous carrier particles and micronized drug

Publications (1)

Publication Number Publication Date
MA38397A1 true MA38397A1 (fr) 2018-01-31

Family

ID=50478894

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38397A MA38397A1 (fr) 2013-03-14 2014-03-13 Agglomérats inhalables de particules de support poreuses et médicament micronisé

Country Status (22)

Country Link
US (2) US9452139B2 (OSRAM)
EP (1) EP2968570A1 (OSRAM)
JP (1) JP6374414B2 (OSRAM)
KR (1) KR20150129716A (OSRAM)
CN (1) CN105188757B (OSRAM)
AU (2) AU2014229265A1 (OSRAM)
BR (1) BR112015021814A2 (OSRAM)
CA (1) CA2905615A1 (OSRAM)
CL (1) CL2015002632A1 (OSRAM)
EA (1) EA201591729A1 (OSRAM)
GT (1) GT201500295A (OSRAM)
HK (1) HK1212616A1 (OSRAM)
IL (1) IL240963A (OSRAM)
MA (1) MA38397A1 (OSRAM)
MX (1) MX2015012814A (OSRAM)
PE (1) PE20151655A1 (OSRAM)
PH (1) PH12015501882A1 (OSRAM)
SA (1) SA515361055B1 (OSRAM)
SG (1) SG11201506397QA (OSRAM)
TN (1) TN2015000395A1 (OSRAM)
WO (1) WO2014141135A1 (OSRAM)
ZA (1) ZA201505768B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
WO2014118532A1 (en) * 2013-01-31 2014-08-07 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
MX2016012641A (es) * 2014-03-27 2016-12-14 Novartis Ag Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
WO2016142708A2 (en) * 2015-03-10 2016-09-15 Cipla Limited Pharmaceutical composition
US10423736B2 (en) * 2015-08-28 2019-09-24 University Of British Columbia Methods and systems for simulating hydrodynamics in gas-solid fluidized beds
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
US20200324064A1 (en) * 2019-04-10 2020-10-15 Cai Gu Huang Inhalation Device for Administering Powdered Pharmaceutical Composition
WO2020247376A1 (en) * 2019-06-03 2020-12-10 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021030307A1 (en) * 2019-08-15 2021-02-18 Abbott Laboratories Nutritional powder manufacturing process using micronization, and powder composition
US11717517B2 (en) * 2020-04-13 2023-08-08 Universitatsspital Basel LSD dose identification
CN114344285B (zh) * 2020-10-14 2023-11-14 江苏恒瑞医药股份有限公司 改良的可吸入团聚物
CN116546980A (zh) * 2020-12-11 2023-08-04 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
CN113318097A (zh) * 2021-04-29 2021-08-31 珠海瑞思普利医药科技有限公司 一种抗特发性肺纤维化的粉雾剂及制备方法
CN116785246A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 一种药物微球及含其的气雾剂
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
NZ243314A (en) 1991-06-26 1994-07-26 Schering Corp Powder dispenser; single metered dose rotated to dispensing conduit
US5829434A (en) 1992-12-18 1998-11-03 Schering Corporation Inhaler for powdered medications
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
HU220472B1 (hu) 1994-09-21 2002-02-28 Inhale Therapeutic Systems Eljárás és készülék por aeroszolosítására, valamint a készülékben alkalmazott adagolócső-egység
ATE209053T1 (de) 1996-01-03 2001-12-15 Glaxo Group Ltd Inhaliervorrichtung
EP0883415B1 (en) 1996-02-21 2002-05-02 Schering Corporation Powdered medication inhaler
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2195121T3 (es) 1996-11-11 2003-12-01 Christian R Noe Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
KR100813784B1 (ko) 1999-05-28 2008-03-13 넥타르 테라퓨틱스 에어로졸화된 약물의 계량된 양을 투여하는 장치 및 방법
US20010029947A1 (en) 1999-12-17 2001-10-18 Steve Paboojian Receptacles to facilitate the extraction of powders
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2004054556A1 (en) 2002-12-13 2004-07-01 Adagit Pharmaceutical porous particles
KR101066788B1 (ko) 2003-04-09 2011-09-21 노바르티스 아게 공기 입구 차폐 부재를 갖춘 에어로졸화 장치
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
PL1718353T3 (pl) 2004-02-24 2020-06-01 Microdose Therapeutx, Inc. Urządzenie do dostarczania leku na bazie strugi syntetycznej
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008000839A1 (en) 2006-06-30 2008-01-03 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
RU2463085C2 (ru) 2006-10-25 2012-10-10 Новартис Аг Аппарат для распыления порошка, способ его изготовления и применения и его компоненты
RU2497524C2 (ru) 2008-05-15 2013-11-10 Новартис Аг Внутрилегочное введение флуорохинолона
KR101290893B1 (ko) 2009-04-09 2013-07-29 노파르티스 아게 피롤리디늄 염의 제조 방법
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR101730684B1 (ko) 2010-04-01 2017-04-26 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말을 위한 담체 입자 제조 방법
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) * 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
PE20151655A1 (es) 2015-11-26
PH12015501882A1 (en) 2015-12-07
SA515361055B1 (ar) 2016-11-13
CA2905615A1 (en) 2014-09-18
AU2017203258A1 (en) 2017-06-08
AU2017203258B2 (en) 2019-06-20
CL2015002632A1 (es) 2016-03-28
US20140302147A1 (en) 2014-10-09
BR112015021814A2 (pt) 2017-07-18
IL240963A (en) 2017-05-29
US9744178B2 (en) 2017-08-29
AU2014229265A1 (en) 2015-09-03
GT201500295A (es) 2017-09-28
EP2968570A1 (en) 2016-01-20
ZA201505768B (en) 2017-03-29
KR20150129716A (ko) 2015-11-20
HK1212616A1 (zh) 2016-06-17
US9452139B2 (en) 2016-09-27
US20160354388A1 (en) 2016-12-08
JP2016512494A (ja) 2016-04-28
CN105188757A (zh) 2015-12-23
CN105188757B (zh) 2019-04-30
MX2015012814A (es) 2016-02-03
TN2015000395A1 (en) 2017-01-03
WO2014141135A1 (en) 2014-09-18
SG11201506397QA (en) 2015-09-29
IL240963A0 (en) 2015-11-30
EA201591729A1 (ru) 2016-05-31
JP6374414B2 (ja) 2018-08-15

Similar Documents

Publication Publication Date Title
MA38397A1 (fr) Agglomérats inhalables de particules de support poreuses et médicament micronisé
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
DE60129573D1 (de) Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
UA107499C2 (uk) Склад сухого порошку, який містить антимускариновий засіб
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
BR112015020443A2 (pt) desamorfização de formulações secadas por atomização via mistura por atomização
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
EP3404020A4 (en) PYRIDINOL DERIVATIVE OR PHARMACEUTICALLY SAFE SALT THEREOF AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE
EA200500387A1 (ru) Композиции для ингаляции с высоким содержанием лекарственных веществ
EA202092922A1 (ru) Фармацевтический состав с улучшенной растворимостью и биологической доступностью
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
EA026665B1 (ru) Твердые формы препаратов иматиниба, ресуспензируемые непосредственно перед применением
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
EA200801447A1 (ru) Фармацевтическая композиция
EA201792159A1 (ru) Способ получения сухих порошкообразных смесей
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
MA35698B1 (fr) Nouvelle composition du 3,4-diaminopyridin pour le traitement de la fatigabilité musculaire associée à des troubles neurovégétatifs.
EA201171014A1 (ru) Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней
TH80301A (th) สารประกอบทางเคมี